Patents Assigned to BEIJING INNOCARE PHARMA TECH CO., LTD.
-
Patent number: 11945792Abstract: The present invention relates to various crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide. The present invention also relates to pharmaceutical compositions comprising the crystalline forms.Type: GrantFiled: March 3, 2021Date of Patent: April 2, 2024Assignee: Beijing Innocare Pharma Tech Co., LtdInventors: Xiangyang Chen, Zuopeng Wang, Liqin Yu
-
Patent number: 11878987Abstract: The present invention relates to a compound, a pharmaceutical composition comprising the compound, the method for the preparation thereof, and the use thereof as TRK inhibitors. The compound is a compound as shown in the following formula I, and isomers, prodrugs, solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof. The present invention also relates to use of the compound in treating or preventing diseases mediated by TRK, such as cancers, and method for treating such diseases using the compounds of the present invention.Type: GrantFiled: June 25, 2019Date of Patent: January 23, 2024Assignee: Beijing Innocare Pharma Tech Co., Ltd.Inventors: Norman Xianglong Kong, Chao Zhou, Zhixiang Zheng
-
Patent number: 11572353Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 7, 2021Date of Patent: February 7, 2023Assignee: Beijing Innocare Pharma Tech Co., Ltd.Inventors: Xiangyang Chen, Yingxiang Gao, Norman Xianglong Kong
-
Patent number: 11389445Abstract: The present invention relates to a novel pentafluorosulfanyl-substituted amide compound that regulates or inhibits indoleamine 2,3-dioxygenase (IDO) activity, its preparation method and its application in medicine. Specifically, the present invention relates to a compound represented by general formula (I) and pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof, application of the compound or pharmaceutically acceptable salt thereof for treating and/or preventing related disorders mediated by IDO, especially tumors, and a method for preparing the compound or pharmaceutically acceptable salt thereof. The present invention also relates to the preparation of the compound or pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof for the treatment and/or prevention of IDO-mediated related disorders, especially for use in tumor treatment.Type: GrantFiled: January 28, 2019Date of Patent: July 19, 2022Assignee: Beijing Innocare Pharma Tech Co., Ltd.Inventors: Xiangyang Chen, Yucheng Pang
-
Patent number: 11059805Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 10, 2020Date of Patent: July 13, 2021Assignee: Beijing Innocare Pharma Tech Co., Ltd.Inventors: Xiangyang Chen, Yingxiang Gao, Norman Xianglong Kong
-
Patent number: 11046682Abstract: The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I?), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I?) is the same as defined in the specification.Type: GrantFiled: August 16, 2017Date of Patent: June 29, 2021Assignee: Beijing Innocare Pharma Tech Co., Ltd.Inventors: Xiangyang Chen, Yingxiang Gao
-
Patent number: 10710981Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 14, 2019Date of Patent: July 14, 2020Assignee: BEIJING INNOCARE PHARMA TECH CO., LTD.Inventors: Xiangyang Chen, Yingxiang Gao, Norman Xianglong Kong
-
Patent number: 10336755Abstract: The present invention relates to pyrazole fused-ring derivatives, their preparation methods, and use thereof in medicine. In particular, the present invention relates to a novel derivative represented by formula (I), and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same and a method for preparing the same. The present invention also relates to use of the derivatives and the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising the same in the preparation of therapeutic agents, in particular Bruton tyrosine kinase inhibitors, and preparing a medicament for treating and/or preventing tumors and inflammatory associated diseases. The substituents on formula (I) are defined same as in the specification.Type: GrantFiled: December 28, 2016Date of Patent: July 2, 2019Assignee: Beijing Innocare Pharma Tech Co., Ltd.Inventors: Xiangyang Chen, Yucheng Pang
-
Publication number: 20190016721Abstract: The present invention relates to pyrazole fused-ring derivatives, their preparation methods, and use thereof in medicine. In particular, the present invention relates to a novel derivative represented by formula (I), and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same and a method for preparing the same. The present invention also relates to use of the derivatives and the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising the same in the preparation of therapeutic agents, in particular Bruton tyrosine kinase inhibitors, and preparing a medicament for treating and/or preventing tumors and inflammatory associated diseases. The substituents on formula (I) are defined same as in the specification.Type: ApplicationFiled: December 28, 2016Publication date: January 17, 2019Applicant: Beijing InnoCare Pharma Tech Co., Ltd.Inventors: Xiangyang Chen, Yucheng Pang
-
Patent number: 9951056Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).Type: GrantFiled: September 29, 2014Date of Patent: April 24, 2018Assignee: BEIJING INNOCARE PHARMA TECH CO., LTD.Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill